VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer

Molecular Cancer Therapeutics

Volumn 12, Issue 2, 2013, Pages 151-161

  Hart, Stefan ^a   Novotny Diermayr, Veronica ^a   Goh, Kee Chuan ^a   Williams, Meredith ^a   Tan, Yong Cheng ^a   Ong, Lai Chun ^a   Cheong, Albert ^a   Ng, Bee Kheng ^a   Amalini, Chithra ^a   Madan, Babita ^a   Nagaraj, Harish ^a   Jayaraman, Ramesh ^a   Pasha, Khalid M ^a   Ethirajulu, Kantharaj ^a   Chng, Wee Joo ^b,c   Mustafa, Nurulhuda ^b   Goh, Boon Cher ^b   Benes, Cyril ^d   McDermott, Ultan ^e   Garnett, Mathew ^e   Dymock, Brian ^a   Wood, Jeanette M ^a   more..

^a S BIO Pte Ltd   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d HARVARD MEDICAL SCHOOL   (United States)

^e WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LIPID; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE; UNCLASSIFIED DRUG; VS 5584;

ANIMAL CELL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TISSUE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG POTENTIATION; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; IC 50; MALE; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; STOMACH TUMOR;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; MORPHOLINES; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PTEN PHOSPHOHYDROLASE; PURINES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874041832     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0466     Document Type: Article

References (35)

1. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010; 11:329-41.
2. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9:550-62.
3. Vanhaesebroeck B, Vogt PK, Rommel C. PI3K: from the bench to the clinic and back. CurrTop Microbiol Immunol 2010; 347:1-19.
4. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8:627-44.
5. Huang S, Bjornsti MA, Houghton PJ. Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther 2003; 2:222-32.
6. Yea SS, Fruman DA. Cell signaling. New mTOR targets Grb attention. Science 2011; 332:1270-1.
7. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12:9-22.
8. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22:159-68.
9. Chen D, Williams Minventors S'BIO PTE LTD., assignee. Pyrimidine substituted purine compounds as kinase inhibitors. PCT application WO2010114484. 2010 Oct 7.
10. Borrell-Pages M, Rojo F, Albanell J, Baselga J, Arribas J. TACE is required forthe activation of the EGFR by TGF-alpha in tumors. EMBO J 2003; 22:1114-24.
11. Williams M, Hart S, Bonday Z, Goh KC, Diermayr-Novotny V, Loh YK, et al. A novel series of tetrasubstituted purines potently inhibit mTOR and PI3K, exhibit striking selectivity and demonstrate good pathway inhibition in vivo. In: Proceedings of the Special Conference of the American Association for Cancer Research - Targeting PI3K/ mTOR Signaling in Cancer; 2011 Feb 24-27; San Francisco, CA. Philadelphia (PA): AACR; 2011. Abstract nr B26.
12. Hart S, Soh CK, Bonday Z, Goh KC, Diermayr-Novotny V, Loh YK, et al. SB2343, a novel tetra substituted purine, inhibits mTOR and PI3K equipotently, and has favorable pharmacokinetic and pharmacodynamic properties and is orally efficacious. In: Proceedings of the Special Conference of the American Association for Cancer Research - Targeting PI3K/mTOR Signaling in Cancer; 2011 Feb 24-27; San Francisco, CA. Philadelphia (PA): AACR; 2011. Abstract nr A25.
13. Williams M, Hart S, Chen D, Kumar H, Blanchard S, Poulsen A, et al. Discovery of 5-(2-morpholino-9H-purin-6-yl)pyrimidin-2-amine derivate (SB2343), a highly selective pan-PI3/mTOR kinase inhibitor. J Med Chem. In preparation 2013.
14. Clarke R. Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents in vivo in breast cancer and other models. Breast Cancer Res Treat 1997; 46:255-78.
15. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012; 483:570-5.
16. Garnett MJ, McDermott U. Exploiting genetic complexity in cancerto improve therapeutic strategies. Drug Discov Today 2012; 17:188-93.
17. Lamm W, Vogl UM, Bojic M, Zielinski C, Klingler C, Kramer G, et al. Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma. Acta Oncol 2011; 51:101-6.
18. Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P, Bouscary D. PI3Kand mTOR signaling pathways in cancer: new data on targeted therapies. Curr Oncol Rep 2012; 14:129-38.
19. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66:1500-8.
20. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009; 7:e38.
21. Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 2008; 27:5527-41.
22. 0 kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 2010; 16:3670-83.
23. Graupera M, Guillermet-Guibert J, Foukas LC, Phng LK, Cain RJ, Salpekar A, et al. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 2008; 453:662-6.
24. Schnell CR, Stauffer F, Allegrini PR, O'Reilly T, McSheehy PM, Dartois C, et al. Effects of the dual phosphatidylinositol 3-kinase/ mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res 2008; 68: 6598-607.
25. Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 2010; 60:222-43.
26. McCubrey JA, Steelman LS, Kempf CR, Chappell WH, Abrams SL, Stivala F, et al. Therapeutic resistance resulting from mutations in Raf/ MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol 2011; 226:2762-81.
27. Liu M, Howes A, Lesperance J, Stallcup WB, Hauser CA, Kadoya K, et al. Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer. Cancer Res 2005; 65: 5325-36.
28. Bianco R, Garofalo S, Rosa R, Damiano V, Gelardi T, Daniele G, et al. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 2008; 98:923-30.
29. Ciraolo E, Morello F, Hirsch E. Present and future of PI3K pathway inhibition in cancer: perspectives and limitations. Curr Med Chem 2011; 18:2674-85.
30. Bowles DW, Jimeno A. New phosphatidylinositol 3-kinase inhibitors for cancer. Expert Opin Investig Drugs 2011; 20:507-18.
31. Wallin JJ, Edgar KA, Guan J, Berry M, Prior WW, Lee L, et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther 2011; 10:2426-36.
32. Salphati L, Wong H, Belvin M, Bradford D, Edgar KA, Prior WW, et al. Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug Metab Dispos 2010; 38:1436-42.
33. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, et al. Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012; 30:282-90.
34. Kurtz JE, Ray-Coquard I. PI3 kinase inhibitors in the clinic: an update. Anticancer Res 2012; 32:2463-70.
35. Bartholomeusz C, Gonzalez-Angulo AM. Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets 2012; 16:121-30.